BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 31247975)

  • 21. [Familial thyroid carcinomas].
    Schmid KW; Ting S; Sheu SY
    Pathologe; 2010 Oct; 31(6):485-8. PubMed ID: 20852865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.
    Cirello V; Colombo C; Karapanou O; Pogliaghi G; Persani L; Fugazzola L
    Front Endocrinol (Lausanne); 2020; 11():589340. PubMed ID: 33488516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The FOXE1 locus is a major genetic determinant for familial nonmedullary thyroid carcinoma.
    Bonora E; Rizzato C; Diquigiovanni C; Oudot-Mellakh T; Campa D; Vargiolu M; Guedj M; ; McKay JD; Romeo G; Canzian F; Lesueur F
    Int J Cancer; 2014 May; 134(9):2098-107. PubMed ID: 24127282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial follicular cell-derived thyroid carcinoma.
    Son EJ; Nosé V
    Front Endocrinol (Lausanne); 2012; 3():61. PubMed ID: 22654876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
    Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
    Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
    Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
    J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Familial nonmedullary thyroid carcinoma.
    Mazeh H; Sippel RS
    Thyroid; 2013 Sep; 23(9):1049-56. PubMed ID: 23734600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An update on familial nonmedullary thyroid cancer.
    Ammar SA; Alobuia WM; Kebebew E
    Endocrine; 2020 Jun; 68(3):502-507. PubMed ID: 32162184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Penetrance of a rare familial mutation predisposing to papillary thyroid cancer.
    Saporito D; Brock P; Hampel H; Sipos J; Fernandez S; Liyanarachchi S; de la Chapelle A; Nagy R
    Fam Cancer; 2018 Jul; 17(3):431-434. PubMed ID: 29027612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer.
    Na KY; Kim RM; Song EM; Lee JH; Lee J; Soh EY
    J Surg Oncol; 2012 Jan; 105(1):10-4. PubMed ID: 21826673
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical behavior and genetics of nonsyndromic, familial nonmedullary thyroid cancer.
    Bauer AJ
    Front Horm Res; 2013; 41():141-8. PubMed ID: 23652675
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates.
    Cameselle-Teijeiro JM; Mete O; Asa SL; LiVolsi V
    Endocr Pathol; 2021 Mar; 32(1):77-101. PubMed ID: 33495912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted DNA Sequencing Detects Mutations Related to Susceptibility among Familial Non-medullary Thyroid Cancer.
    Yu Y; Dong L; Li D; Chuai S; Wu Z; Zheng X; Cheng Y; Han L; Yu J; Gao M
    Sci Rep; 2015 Nov; 5():16129. PubMed ID: 26530882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HABP2 Gene Mutations Do Not Cause Familial or Sporadic Non-Medullary Thyroid Cancer in a Highly Inbred Middle Eastern Population.
    Alzahrani AS; Murugan AK; Qasem E; Al-Hindi H
    Thyroid; 2016 May; 26(5):667-71. PubMed ID: 26906432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Familial non-medullary thyroid cancer: a critical review.
    Capezzone M; Robenshtok E; Cantara S; Castagna MG
    J Endocrinol Invest; 2021 May; 44(5):943-950. PubMed ID: 33025555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Familial nonmedullary thyroid cancer: a review of the genetics.
    Khan A; Smellie J; Nutting C; Harrington K; Newbold K
    Thyroid; 2010 Jul; 20(7):795-801. PubMed ID: 20465534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
    Zhang T; Xing M
    J Natl Cancer Inst; 2016 Jun; 108(6):djv415. PubMed ID: 26832773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Familial non medullary thyroid carcinoma: Beyond the syndromic forms.
    Orois A; Mora M; Halperin I; Oriola J
    Endocrinol Diabetes Nutr (Engl Ed); 2021 Apr; 68(4):260-269. PubMed ID: 34266638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Familial nonmedullary thyroid cancer: screening, clinical, molecular and genetic findings.
    Navas-Carrillo D; Ríos A; Rodríguez JM; Parrilla P; Orenes-Piñero E
    Biochim Biophys Acta; 2014 Dec; 1846(2):468-76. PubMed ID: 25218916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum.
    Zhou J; Singh P; Yin K; Wang J; Bao Y; Wu M; Pathak K; McKinley SK; Braun D; Lubitz CC; Hughes KS
    Ann Surg Oncol; 2021 Oct; 28(11):6590-6600. PubMed ID: 33660127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.